Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
2011
Receptor Tyrosine Kinases as Targets in Rhabdomyosarcoma
publication
Evidence: moderate
Author Information
Author(s): Lisa E. S. Crose, Corinne M. Linardic
Primary Institution: Duke University Medical Center
Hypothesis
Targeting receptor tyrosine kinases (RTKs) may improve treatment outcomes for rhabdomyosarcoma (RMS).
Conclusion
Targeting RTKs in RMS shows promise for improving treatment outcomes, especially for high-risk patients.
Supporting Evidence
- Rhabdomyosarcomas are the most common soft tissue sarcomas in children.
- Current treatments for high-risk RMS patients are inadequate.
- RTKs have been identified as druggable targets in RMS.
- Preclinical studies show that inhibiting RTKs can block tumor growth.
Takeaway
Rhabdomyosarcoma is a type of cancer in kids, and scientists think that blocking certain proteins called RTKs could help treat it better.
Methodology
The review discusses various RTKs implicated in RMS and their potential as therapeutic targets based on preclinical studies.
Limitations
The review does not provide new experimental data but summarizes existing research.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website